首页> 外国专利> PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

机译:慢性阻塞性肺疾病患者的临床结果预测

摘要

FIELD: medicine; diagnostics.;SUBSTANCE: present invention relates to diagnostics, namely to a method for estimating the mortality risk of COPD patients for 2 years. Method for estimating the mortality risk of COPD patients for 2 years, where the method involves the steps of: providing a blood sample, serum, plasma, cerebrospinal fluid, urine, saliva, sputum or pleural effusions from said patient; determining in said sample the level of a precursor fragment of at least 12 amino acids length of at least one biomarker, wherein said biomarker is selected from a group consisting of procalcitonin (PCT; SEQ ID NO: 12), PCT 1-116, PCT 2-116, PCT 3-116, mid-regional prodreno-medullin (MR-proADM; SEQ ID NO: 7), a medium region atrial natriuretic peptide (MR-pro-ANP), copectin (SEQ ID NO: 10), with certain boundaries of passing the marker; determining BODE index parameters, then performing correlation of said level of at least one biomarker in combination with said parameters of BODE index, to assess the mortality risk for 2 years of the COPD patients, to this end, assessing the score for the biomarker based on different transmission boundaries; fixing the score in each of the tested BODE index parameters (B and D or B, D and O); scores are summed up in a combined score, where score of 0 to 3 corresponds to a low mortality rate in COPD patients for 2 years, score of 4 to 6 corresponds to an average mortality rate of COPD patients for 2 years, and value of points from 7 to 13 corresponds to high risk of mortality of COPD patients for 2 years.;EFFECT: method described above enables reliable estimating of mortality risk in COPD patients for 2 years.;6 cl, 36 dwg, 1 ex, 6 tbl
机译:领域:医学;诊断方法;物质:本发明涉及诊断方法,即一种估计COPD患者2年死亡风险的方法。评估COPD患者2年死亡风险的方法,该方法包括以下步骤:提供该患者的血样,血清,血浆,脑脊液,尿液,唾液,痰或胸腔积液;确定所述样品中至少一种生物标记的至少12个氨基酸长度的前体片段的水平,其中所述生物标记选自降钙素(PCT; SEQ ID NO:12),PCT 1-116,PCT 2-116,PCT 3-116,中部区域肾上腺髓质素(MR-proADM; SEQ ID NO:7),中型心房利钠肽(MR-pro-ANP),果胶(SEQ ID NO:10),在通过标记的一定范围内;确定BODE指数参数,然后将所述至少一种生物标记物的水平与BODE指数参数进行关联,以评估COPD患者2年的死亡风险,为此,根据以下指标评估生物标记物的得分不同的传输边界;将分数固定在每个测试的BODE索引参数(B和D或B,D和O)中;得分被汇总为一个综合得分,其中0到3分对应于COPD患者2年的低死亡率,4到6分对应于COPD患者2年的平均死亡率,以及分值从7到13对应于COPD患者2年的高死亡风险;效果:上述方法可以可靠地估算2年COPD患者的死亡风险; 6 cl,36 dwg,1 ex,6 tbl

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号